Amicus Therapeutics, Inc. (FOLD) Tops Q1 EPS by 1c; Guides In-line
Tweet
Share
E-mailGet Alerts FOLD Hot Sheet
Price: $10.17 -3.51%
Revenue Growth %: +30.2%
Financial Fact:
Total operating expenses: 46.72M
Today's EPS Names:
WF, CWBC, GLTO, More
Revenue Growth %: +30.2%
Financial Fact:
Total operating expenses: 46.72M
Today's EPS Names:
WF, CWBC, GLTO, More
Join SI Premium – FREE
Amicus Therapeutics, Inc. (NASDAQ: FOLD) reported Q1 EPS of ($0.35), $0.01 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $7.52 million.
Amicus continues to expect full-year 2012 operating expenses will total between $37 million to $43 million (Consensus is $40.26 mln), net of anticipated cost sharing and milestones related to the GSK collaboration. Amicus and GSK equally shared development costs for migalastat HCl (monotherapy and co-administration) in 2011, and GlaxSmithKline (NYSE: GSK) is responsible for 75% of these costs in 2012 and beyond, subject to annual and aggregate caps. Amicus is also eligible to receive up to a total of $170 million in development, regulatory and commercial milestones as part of the Fabry collaboration with GSK.
For earnings history and earnings-related data on Amicus Therapeutics, Inc. (FOLD) click here.
Amicus continues to expect full-year 2012 operating expenses will total between $37 million to $43 million (Consensus is $40.26 mln), net of anticipated cost sharing and milestones related to the GSK collaboration. Amicus and GSK equally shared development costs for migalastat HCl (monotherapy and co-administration) in 2011, and GlaxSmithKline (NYSE: GSK) is responsible for 75% of these costs in 2012 and beyond, subject to annual and aggregate caps. Amicus is also eligible to receive up to a total of $170 million in development, regulatory and commercial milestones as part of the Fabry collaboration with GSK.
For earnings history and earnings-related data on Amicus Therapeutics, Inc. (FOLD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- AptarGroup (ATR) Tops Q1 EPS by 11c
- Seacoast Banking Corporation of Florida (SBCF) Tops Q1 EPS by 2c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
